BRIEF-Ablynx reports 9-month revenue of 16.7 mln euros

BRUSSELS Thu Nov 14, 2013 1:12am EST

Related Topics

BRUSSELS Nov 14 (Reuters) - Ablynx NV : * Says 9 months revenues of 16.7 mln euros * Signed exclusive global license agreement with abbvie, potentially worth $840 mln * Deal for development, commercialisation of the anti-il-6r nanobody, alx-0061, in RA and SLE * Net loss for 9-month period was 18.9 mln euros vs 22.3 mln euros last year * Says positive net cash inflow of 0.2 mln euros * Says 9-month operating expenses decreased to 36.2 mln euros vs 45.4 mln last year due to lower research and development costs * Says upfront payments as part of collaborations with Abbvie and Merck Serono were booked in fourth quarter * Started additional anti-rsv nanobody phase i studies; goal to initiate first-in-infant trial in H2 2014 * Last quarter of year has already started strongly with signing of license agreement with Eddingpharm in Greater China

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.